Anping Li
Impact in
- Cancer Research top 1%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
-
- RNA modifications and cancer 4
- Angiogenesis and VEGF in Cancer 3
-
- Cancer-related molecular mechanisms research 6
- MicroRNA in disease regulation 6
- Co-authors
- Kongming Wu (29 shared papers)Ming Yi (14 shared papers)Shuang Qin (10 shared papers)Qian Chu (7 shared papers)Dechao Jiao (4 shared papers)Shengnan Yu (7 shared papers)Suxia Luo (6 shared papers)Tengfei Li (2 shared papers)
- Journals
- Journal of Hematology & Oncology (10 papers)Oncotarget (4 papers)BioMed Research International (2 papers)Experimental Hematology and Oncology (2 papers)Proceedings of the National Academy of Sciences (2 papers)
- Partner nations
- ChinaUnited StatesMacao
In The Last Decade
Anping Li
53 papers receiving 5.0k citations
Anping Li's Hit Papers
Peers
Comparison fields: 5 of 113
- Cancer Research 973
- Oncology 1.6k
- Immunology 1.1k
- Molecular Biology 2.4k
- Pulmonary and Respiratory Medicine 497
Countries citing papers authored by Anping Li
This map shows the geographic impact of Anping Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anping Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anping Li more than expected).
Fields of papers citing papers by Anping Li
This network shows the impact of papers produced by Anping Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anping Li. The network helps show where Anping Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Anping Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The CXCL8-CXCR1/2 pathways in cancer Hit paper breakdown → | 2016 | 491 |
| 2 | Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment Hit paper breakdown → | 2019 | 479 |
| 3 | Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy Hit paper breakdown → | 2019 | 304 |
| 4 | 2019 | 247 | |
| 5 | 2017 | 239 | |
| 6 | 2020 | 186 | |
| 7 | 2015 | 178 | |
| 8 | 2020 | 170 | |
| 9 | The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1 Hit paper breakdown → | 2021 | 169 |
| 10 | 2014 | 167 | |
| 11 | 2016 | 158 | |
| 12 | 2009 | 152 | |
| 13 | 2015 | 150 | |
| 14 | 2017 | 121 | |
| 15 | 2019 | 108 | |
| 16 | 2003 | 108 | |
| 17 | 2006 | 99 | |
| 18 | 2021 | 96 | |
| 19 | 2006 | 91 | |
| 20 | 2018 | 87 |
About Anping Li
Anping Li is a scholar working on Molecular Biology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Immunology, having authored 54 papers that have together received 5.1k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (6 papers), MicroRNA in disease regulation (6 papers), RNA modifications and cancer (4 papers), Renal cell carcinoma treatment (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Immune cells in cancer (3 papers), Angiogenesis and VEGF in Cancer (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). The work is most often cited by research in Cancer Research (973 citations), Oncology (1.6k citations), Immunology (1.1k citations), Molecular Biology (2.4k citations) and Pulmonary and Respiratory Medicine (497 citations). Anping Li has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Kongming Wu, Ming Yi, Shuang Qin, Qian Chu, Dechao Jiao, Shengnan Yu, Suxia Luo, Tengfei Li, Xinwei Han and Qihong Huang. Their work appears in journals such as Journal of Hematology & Oncology, Oncotarget, BioMed Research International, Experimental Hematology and Oncology and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.